Price T Rowe Associates Inc Immunity Bio, Inc. Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
A detailed history of Price T Rowe Associates Inc transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 56,288 shares of IBRX stock, worth $172,241. This represents 0.0% of its overall portfolio holdings.
Number of Shares
56,288
Previous 75,247
25.2%
Holding current value
$172,241
Previous $281,000
48.4%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding IBRX
# of Institutions
229Shares Held
82.3MCall Options Held
1.02MPut Options Held
2.25M-
Vanguard Group Inc Valley Forge, PA17.3MShares$53 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$35 Million0.0% of portfolio
-
State Street Corp Boston, MA9.79MShares$29.9 Million0.0% of portfolio
-
Morgan Stanley New York, NY4.01MShares$12.3 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.84MShares$11.8 Million0.0% of portfolio
About ImmunityBio, Inc.
- Ticker IBRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 400,304,000
- Market Cap $1.22B
- Description
- ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...